Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Combined With PD-L1 Inhibitor and Chemotherapy in First-Line ES-SCLC
NCT07373964Phase 2Recruiting
- Sponsor
- China Medical University
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in small cell lung cancer (SCLC), sponsored by China Medical University. Primary endpoint: Progression-Free Survival at 24 months. Started Oct 2025; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07373964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07373964.